Inovio Pharmaceuticals (INO) News Today $1.84 -0.01 (-0.27%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Investors Look to End Week on Strong Note as US Futures Rise in Friday's PremarketDecember 13, 2024 | msn.comInovio Pharmaceuticals Prices $30 Mln Public Offering With WarrantsDecember 13, 2024 | markets.businessinsider.comInovio announces common stock and warrants offering, no amount givenDecember 13, 2024 | markets.businessinsider.comINOVIO Announces Pricing of $30 Million Public OfferingDecember 13, 2024 | prnewswire.comInovio Down 20% After Hours on Planned Stock and Warrant SaleDecember 12, 2024 | marketwatch.comINOVIO Announces Proposed Public OfferingDecember 12, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Rating of "Moderate Buy" by AnalystsDecember 12, 2024 | americanbankingnews.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to thDecember 12, 2024 | marketbeat.comINOVIO Reports Data From Retrospective Trial Evaluating INO-3107 - Quick FactsDecember 3, 2024 | markets.businessinsider.comInovio’s INO-3107 shows efficacy in Phase 1/2 RRP trialDecember 3, 2024 | markets.businessinsider.comNew Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 TrialDecember 3, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest Up 7.1% in NovemberInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 3,750,000 shares, a growth of 7.1% from the October 31st total of 3,500,000 shares. Based on an average daily volume of 336,300 shares, the short-interest ratio is currently 11.2 days. Approximately 14.5% of the company's stock are short sold.December 3, 2024 | marketbeat.comINOVIO Reports Inducement Grant Under Inducement PlanNovember 29, 2024 | prnewswire.comWhat is HC Wainwright's Estimate for INO FY2024 Earnings?Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of Inovio Pharmaceuticals in a research note issued to investors on Monday, November 18th. HC Wainwright analyst R. Selvaraju now expects that the biophaNovember 20, 2024 | marketbeat.comCautious Hold Recommendation on Inovio Pharmaceuticals Amid Financial Challenges and Competitive PressuresNovember 19, 2024 | markets.businessinsider.comInovio price target lowered to $5 from $12 at H.C. WainwrightNovember 18, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Inovio PharmaceuticalsNovember 18, 2024 | benzinga.comInovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $5.00 by Analysts at HC WainwrightHC Wainwright reduced their price target on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a "neutral" rating for the company in a research report on Monday.November 18, 2024 | marketbeat.comOppenheimer Lowers Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $15.00Oppenheimer decreased their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating for the company in a research report on Monday.November 18, 2024 | marketbeat.comInovio Pharmaceuticals: Strategic Progress and Promising Pipeline Justify Buy RatingNovember 18, 2024 | markets.businessinsider.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have issued aNovember 17, 2024 | marketbeat.comINOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 16, 2024 | finanznachrichten.deRBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)November 16, 2024 | markets.businessinsider.comInovio Pharmaceuticals Q3 Earnings Tops Estimates, Lifts Retail SentimentNovember 16, 2024 | msn.comInovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)November 16, 2024 | finance.yahoo.comRoyal Bank of Canada Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $6.00Royal Bank of Canada lowered their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating for the company in a research note on Friday.November 15, 2024 | marketbeat.comInovio Pharmaceuticals Advances DNA Medicine DevelopmentNovember 15, 2024 | markets.businessinsider.comInovio Pharmaceuticals (INO) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | fool.comInovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s BullishNovember 15, 2024 | msn.comInovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comInovio Pharmaceuticals Inc. Q3 Loss NarrowsNovember 14, 2024 | markets.businessinsider.comINOVIO Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | prnewswire.comA Preview Of Inovio Pharmaceuticals's EarningsNovember 14, 2024 | benzinga.comImmunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 TrialNovember 13, 2024 | prnewswire.comINOVIO Set to Unveil Q3 2024 Financial Results and Business Insights on November 14!November 12, 2024 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Outset Medical (OM), Pacira Pharmaceuticals (PCRX) and Allakos (ALLK)November 8, 2024 | markets.businessinsider.comInovio Pharmaceuticals (INO) Set to Announce Earnings on ThursdayInovio Pharmaceuticals (NASDAQ:INO) will be releasing earnings after the market closes on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comINOVIO to Present at Upcoming Scientific ConferencesNovember 6, 2024 | prnewswire.comINOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024November 6, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Moderate Buy" by AnalystsInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommOctober 23, 2024 | marketbeat.comInovio’s INO-3107 shows efficacy in recurrent respiratory papillomatosisOctober 22, 2024 | markets.businessinsider.comINOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRPOctober 21, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest UpdateInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totalling 3,340,000 shares, a growth of 9.5% from the September 15th total of 3,050,000 shares. Currently, 13.0% of the shares of the stock are sold short. Based on an average daily volume of 329,200 shares, the days-to-cover ratio is currently 10.1 days.October 16, 2024 | marketbeat.comInovio Pharmaceuticals (NASDAQ:INO) Stock, Short Interest ReportOctober 8, 2024 | benzinga.comInovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the dayOctober 5, 2024 | marketwatch.comInovio Pharmaceuticals (NASDAQ:INO) Price Target Lowered to $7.00 at Royal Bank of CanadaRoyal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $8.00 to $7.00 and set a "sector perform" rating on the stock in a research report on Friday.October 4, 2024 | marketbeat.comINOVIO Reports Inducement Grants Under Inducement PlanOctober 2, 2024 | prnewswire.comINOVIO to Present at Upcoming Scientific ConferencesOctober 1, 2024 | prnewswire.comInovio Pharmaceuticals: Takes Another Torpedo But Keeps On SailingSeptember 30, 2024 | seekingalpha.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and three haSeptember 28, 2024 | marketbeat.com Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now INO Media Mentions By Week INO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INO News Sentiment▼0.090.60▲Average Medical News Sentiment INO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INO Articles This Week▼03▲INO Articles Average Week Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alpha Tau Medical News Profound Medical News Utah Medical Products News Beauty Health News Accuray News KORU Medical Systems News Orchestra BioMed News InfuSystem News Sight Sciences News BrainsWay News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INO Stock Alerts